Immune checkpoint inhibition (ICI) with PD-1 but not PD-L1 inhibitors3 or CTLA-44 inhibitors has activity in recurrent/metastatic HNSCC and improves survival in the first-line setting5,6 as well as in patients previously treated with cisplatin.7 The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.